ArticleNeuropsychiatric disease and treatment2006
Rizatriptan in the treatment of migraine.
Article in Neuropsychiatric disease and treatment, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 42 citations in OpenAlex.
- Migraine Management in Japan: Current Approaches and Science Narrative Including an Evidence-based Review.Internal medicine (Tokyo, Japan) · 2026Review
- Role of Phytocompounds for Effective Management of Migraine: Current and Future Prospectives.Central nervous system agents in medicinal chemistry · 2025Review
- Synthesis and Biological Properties of Isatin-indole Hybrids: A Review.Mini reviews in medicinal chemistry · 2025Review
- Novel (+)-Neoisopulegol-BasedInternational journal of molecular sciences · 2021Article
- Development of Mucoadhesive Buccal Film for Rizatriptan: In Vitro and In Vivo Evaluation.Pharmaceutics · 2021Article
- Placebo effects and the molecular biological components involved.General psychiatry · 2019Review
- New formulation and approach for mucoadhesive buccal film of rizatriptan benzoate.Progress in biomaterials · 2017Article
- Migraine - a suitable case for treatment?Neuropsychiatric disease and treatment · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Migraine is a common, disabling disorder associated with considerable personal and societal burden. Current guidelines recommend triptans for the acute treatment of migraine unlikely to respond to less effective therapies. Rizatriptan is a second-generation triptan available in tablet or orally disintegrating tablet (wafer) formulations that offers several advantages over other members of its class. Rizatriptan is rapidly absorbed from the gastrointestinal tract and achieves maximum plasma concentrations more quickly than other triptans, providing rapid pain relief. Clinical trials have shown that rizatriptan is at least as effective or superior to other oral migraine-specific agents in the acute treatment of migraine, and has more consistent long-term efficacy across multiple migraine attacks. Rizatriptan has a favorable tolerability profile, and patients have reported greater satisfaction and a preference for rizatriptan over other migraine-specific agents. Improvements in quality of life reported with rizatriptan are consistent with its favorable efficacy and tolerability profiles. Notably, multi-attribute decision models that combine clinical data with patient- and physician-reported treatment preferences have identified rizatriptan as one of three triptans closest to a hypothetical "ideal". The efficacy and tolerability of rizatriptan for the acute treatment of migraine have thus been well established.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.